Ultragenyx Initiates Submission Of BLA To The U.S. FDA For DTX401 AAV Gene Therapy
Aug 18 (Reuters) - Ultragenyx Pharmaceutical Inc RARE.O:
ULTRAGENYX INITIATES ROLLING SUBMISSION OF BIOLOGICS LICENSE APPLICATION (BLA) TO U.S. FDA FOR DTX401 AAV GENE THERAPY FOR THE TREATMENT OF GLYCOGEN STORAGE DISEASE TYPE IA (GSDIA)
ULTRAGENYX PHARMACEUTICAL INC - PLANS TO COMPLETE FULL BLA SUBMISSION IN Q4 2025
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Recommended Articles
Featured Tools
Top News
Musk’s XChat Is Coming to App Store, Meta, Apple and Finance World Are Trembling

What is the CLARITY Act? 2026 Guide to US Crypto Regulation and Stablecoin Yield Rules

Anthropic IPO 2026: What the Claude Mythos Release Delay Means for Investors and Stock Valuation

Microsoft Launches Its Own AI Models and Ditches OpenAI Dependence - Is MSFT Stock a Buy at $370?

Anthropic Claude Mythos Preview Sparks Wall Street Panic: Bessent, Powell Summon CEOs; Cloudflare Tumbles 8%

Tradingkey






